Singapore has one of Asia’s fastest growing biopharma industries, with forecasts revealing a two-fold trajectory of $68.7 billion in market size by the year 2029, and the country’s healthcare spending expected to contribute to 5.9 percent of its GDP and rising. With active public-private partnerships enabling a reliable and supportive ecosystem for manufacturing, strong investments toward upgraded research infrastructure, and continuous diversification into advanced manufacturing and digital solutions, Singapore’s healthcare sector is poised for rapid growth.
There is tremendous opportunity for pharmaceutical and biotech manufacturers in Singapore, but opportunity breeds competition, with more than 50 biopharma companies having R&D or corporate operations there. For that reason it is essential that pharmaceutical companies effectively communicate their value stories and distinguish their products as being worthy of reimbursement and access in an increasingly crowded market.
Singapore’s Payer Stakeholders
Singapore’s citizens have universal healthcare coverage through a variety of public and private providers. For private insurers, premiums are payed entirely out of pocket, but public insurers offer lower government subsidized rates at the cost of not reimbursing some treatments. Ultimately, 60 percent of healthcare costs for patients come out of pocket as opposed to pure public subsidies. This multi-pronged approach delivers affordable healthcare through the following providers and funds:
- Direct Government subsidies on certain medicines.
- MediShield Life – The basic health insurance plan administered by the Central Provident Fund (CPF) of Singapore. MediShield Life provides universal coverage for Singaporean citizens. MediShield offers options with higher claim limits for hospital bills and some outpatient treatments in exchange for higher premiums.
- Private Integrated Shield Plans – In addition to MediShield Life, there are plans provided by private insurers that often have more expansive coverage.
- Medisave – Every citizen contributes between 4 to 10.5 percent of his or her monthly salary to a Medisave account (percentage varies with the individual’s age and yearly income). The monthly contribution goes toward future personal healthcare expenses or those of an immediate family member.
- Medifund – Medifund provides a safety net for patients who face financial difficulties in paying off their medical bills, even after tapping every other resource available.
Ministry of Health (MOH)
Regulation of the healthcare industry comes under the purview of the Ministry of Health (MOH). The MOH is also the chief authority for determining what medicines, medical devices, and surgeries will be reimbursed by MediShield and by how much healthcare services will be subsidized. Aside from subsidizing healthcare services and governing reimbursement strategy, the MOH distributes grants to innovators whose products in development offer improved efficacy over existing options. This grant process can serve as an initial point of access for innovative products whose price would otherwise disqualify them for reimbursement.
Group Procurement Office and Group Purchasing Office
These agencies support SingHealth and the National Healthcare Group (NHG), two of the largest government hospital systems, in the bulk purchase of required drugs, medical and surgical equipment and other critical healthcare supplies. Because there is no direct government regulation of prices in Singapore, the collective purchasing power of these hospital networks is the key factor in keeping prices low.
- Private hospitals have more leeway in the purchase and dispensation of medications and devices.
Important Points to Keep in Mind
Depending on the risk classification of a drug, the target turn-around time for product registration can take anywhere between 50 and 270 working days. Drugs that have been approved in foreign markets can be placed in an abridged evaluation process.
- Private providers often procure drugs at a much higher cost than their peers in the public sector, due to less collective bulk purchasing powers. At the same time, private hospitals and practices are more willing to administer high cost products that the public system considers inefficient.
- Drugs that are listed under the “Standard Drugs List” or “Medication Assistance Fund” are either heavily subsidized or priced at no more than $1.00 USD per week. The standard drug list is modeled after the WHO essential drug list, but with modifications to suit local disease profiles and practice. It is reviewed on an annual basis by the Drug Advisory Committee.
Implications for Industry
Singapore can be an excellent point of entry to the Asian healthcare market due to the well-established existing healthcare infrastructure and the free-trade agreements between Singapore and its neighbors. This eases the process of achieving regulatory approval and expanding a product’s access into the rest of Asia.
The Health Sciences Authority (HSA) strictly monitors safety and efficacy of products as well as modifies buying practices to ensure that drug prices remain relatively affordable for the general population. The marketing and promotion of innovative products is also tightly controlled. For these reasons, local experience is critical to developing a credible value story for products entering the healthcare market in Singapore. Being able to negotiate approval and access with the HSA and MediShield Life, as well as understanding the nuances of post-launch product support and marketing is the key to taking advantage of the opportunities present in the market.
For a complimentary 30-minute consultation
Vaccines are widely considered among the most significant medical achievements in global health, saving an estimated 2-3 million lives annually. As the world continues to grapple with the impacts of the COVID-19 pandemic, vaccine education and uptake is...
Addition of PRPA enhances network’s industry-leading presence in Europe NEW YORK and PARIS, Oct. 13, 2020 - GLOBALHealthPR (GHPR), the world’s largest network of independent health and science communications agencies, today announced the addition of Paris-based PRPA...
GLOBALHealthPR partner Aurora hosts webinar with leading industry experts As one of the countries hardest-hit by the coronavirus pandemic, the United Kingdom has seen its challenges related to health system response. With this as the backdrop, GLOBALHealthPR's UK...
The impact of the COVID-19 pandemic is being felt worldwide. In response, many of our global partners—dedicated to improving and protecting health—have created initiatives and communications campaigns to curb the spread of misinformation, combat COVID-19 and help...
The Nordic Divide on Fighting COVID-19: Why are Denmark and Sweden Taking Drastically Different Approaches?
Differences provide window of insight into populations and nuances across Scandinavia To outsiders, Denmark and Sweden are often seen as one in the same due in large part to their cultural similarities and geographic proximity. After all, in approximately ten minutes...
Last week, the GLOBALHealthPR community connected virtually to discuss how we can best support our clients and their priorities during the coronavirus pandemic. Leaders from our network of independent healthcare agencies around the globe shared experiences on how best...